DNA double helix cross-linking agent

DNA double helix cross-linking agents are not a single molecular target or receptor; rather they represent a broad class of chemical compounds—primarily bifunctional alkylating agents—that form covalent bonds between nucleotides on opposite strands within the DNA double helix. This process creates interstrand or sometimes intrastrand links that prevent strand separation necessary for essential processes like replication and transcription. The inability to separate the two strands blocks cell division and leads to cytotoxicity—a property exploited therapeutically in chemotherapy against rapidly dividing cancer cells. Common examples include nitrogen mustards, platinum-based drugs like cisplatin, mitomycin C, psoralens activated by UV light, among others. These drugs do not bind a protein target such as an enzyme or receptor; instead they chemically modify nucleic acids directly through their reactive groups. Because "DNA double helix cross-linking agent" refers generically to any compound capable of inducing such lesions—and not an individual gene product/protein—it is not considered a canonical therapeutic target like receptors or enzymes would be; it is more accurately described as a drug mechanism/classification than as a molecular entity itself[1][2][3][4].

Other names

DNA cross-linking agentDNA interstrand cross-linking agentDNA alkylating agent (context-dependent)Interstrand crosslinkerBifunctional alkylating agent (context-dependent)

Drugs in this class typically act by covalently binding to nucleotides on opposite strands of the DNA double helix, forming interstrand or intrastrand cross-links. This prevents the separation and unwinding of the two strands required for replication and transcription. The resulting block leads to inhibition of cell division and ultimately triggers apoptosis if not repaired by cellular mechanisms[1][2][3].